Amarin (AMRN) highlighted recently published data in the Journal of the American Heart Association showing in a post-hoc analysis of the ...

Amarin first introduced its drug in the US as Vascepa in 2012, but only made it available in Europe last year, starting with a German launch last September. It plans to launch the product in up to ...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Amarin Corporation announced the publication of new data in the Journal of the American Heart Association, detailing a post-hoc analysis from the REDUCE-IT study, which found that Icosapent Ethyl ...

StockNews.com downgraded shares of Amarin (NASDAQ:AMRN – Free Report) from a hold rating to a sell rating in a research report released on Tuesday morning. Amarin Trading Up 0.6 % Shares of Amarin ...

He will be responsible for leading Amarin’s global finance organization and will report directly to the Company’s Chief Executive Officer, Aaron Berg. Most recently, Mr. F Amarin (AMRN ...

Austrian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Risk of Cardiovascular Events in Eligible ...

1 Day AMRN -1.65% DJIA 1.39% Russell 2K 1.09% Health Care/Life Sciences 0.59% ...

Amarin has a twelve month low of $0.43 and a twelve month high of $1.37. The stock has a fifty day simple moving average of $0.51 and a 200 day simple moving average of $0.59. Get Amarin alerts ...